CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Achaogen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Achaogen Inc
548 Market Street
#70987
Phone: (650) 800-3636p:650 800-3636 San Francisco, CA  94104  United States Fax: (650) 266-1130f:650 266-1130
Filed for Bankruptcy on 4/15/2019
This company ceased filing statements with the SEC on 8/16/2019.
Case #19-10844, filed in the U.S. Bankruptcy Court for the District of Delaware
This company is no longer actively traded on any major stock exchange.
Business Summary
Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201812/31/2018YesYesYes-Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Secretary, Director BlakeWise 47 7/23/2019 10/1/2015
Chief Restructuring Officer NickCampbell 1/1/2020
Independent Director Kent E.Lieginger 66 3/12/2015 3/12/2015
Independent Director John W.Smither 66 2/20/2014 2/20/2014

Business Names
Business Name
Achaogen Inc
AKAO
AKAOQ

General Information
Number of Employees: 42 (As of 4/1/2019)
Outstanding Shares: 63,879,995 (As of 3/25/2019)
Shareholders: 14
Stock Exchange: OTC
Federal Tax Id: 680533693
Fax Number: (650) 266-1130
Email Address: info@achaogen.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023